SEC Comment Letter 0000000000-26-004178 to Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Inc.
Date: April 23, 2026 · CIK: 0001636651 · Accession: 0000000000-26-004178

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-295218

Date

April 23, 2026

Author

Division of

Form

UPLOAD

Company

Ovid Therapeutics Inc.

Letter

Re: Ovid Therapeutics Inc. Registration Statement on Form S-3 Filed April 21, 2026 File No. 333-295218 Dear Margaret Alexander:

April 23, 2026

Margaret Alexander Chief Executive Officer Ovid Therapeutics Inc. 441 Ninth Avenue, 14th Floor New York, NY 10001

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jaime Chase

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           April 23, 2026

Margaret Alexander
Chief Executive Officer
Ovid Therapeutics Inc.
441 Ninth Avenue, 14th Floor
New York, NY 10001

       Re: Ovid Therapeutics Inc.
           Registration Statement on Form S-3
           Filed April 21, 2026
           File No. 333-295218
Dear Margaret Alexander:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Lauren Hamill at 303-844-1008 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Jaime Chase
</TEXT>
</DOCUMENT>

SecProbe.io